Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment
Open Access
- 28 March 2007
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 156 (6) , 1204-1213
Abstract
Background In melanoma, several signalling pathways are constitutively activated. Among them, the RAS/RAF/MEK/ERK (MAPK) and PI3K/AKT (AKT) signalling pathways are activated through multiple mechanisms and appear to play a major role in melanoma development and progression. Objectives In this study, we examined whether targeting the MAPK and/or AKT signalling pathways would have therapeutic effects against melanoma. Methods Using a panel of pharmacological inhibitors (BAY 43-9006, PD98059, U0126, wortmannin, LY294002) we inhibited the MAPK and AKT signalling pathways at different levels and evaluated the effects on growth, survival and invasion of melanoma cells in monolayer and organotypic skin culture. Results Antiproliferative and proapoptotic effects of inhibitors alone in monolayer culture were disappointing and varied among the different cell lines. In contrast, combined targeting of the MAPK and AKT signalling pathways significantly inhibited growth and enhanced apoptosis in monolayer culture. To verify our data in a more physiological context we incorporated melanoma cells into regenerated human skin mimicking the microenvironment of human melanoma. Combinations of MAPK and AKT inhibitors completely suppressed invasive tumour growth of melanoma cells in regenerated human skin. Conclusions Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment and should encourage further in-depth investigations.Keywords
This publication has 25 references indexed in Scilit:
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanomaFrontiers in Bioscience-Landmark, 2005
- LY-294002 [2-(4-Morpholinyl)-8-phenyl-4 H-1-benzopyran-4-one] Affects Calcium Signaling in Airway Smooth Muscle Cells Independently of Phosphoinositide 3-Kinase InhibitionThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Topical Treatment with Inhibitors of the Phosphatidylinositol 3′-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient MiceCancer Research, 2004
- LY294002 inhibits monocyte chemoattractant protein‐1 expression through a phosphatidylinositol 3‐kinase‐independent mechanismFEBS Letters, 2004
- Exclusion of BRAFV599E as a melanoma susceptibility mutationInternational Journal of Cancer, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Induction of β3-Integrin Gene Expression by Sustained Activation of the Ras-Regulated Raf–MEK–Extracellular Signal-Regulated Kinase Signaling PathwayMolecular and Cellular Biology, 2001
- Human Melanoma Progression in Skin ReconstructsThe American Journal of Pathology, 2000
- A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitroMelanoma Research, 1991